Publication date: Jul 04, 2025
Vitiligo is a chronic autoimmune disease characterized by destruction of pigment-producing melanocytes in the skin. This study explores the patient and treatment history of vitiligo and associated mental health burden in EU5 countries. The cross-sectional global Vitiligo and Life Impact Among International Communities (VALIANT) study recruited people with vitiligo via an online panel and surveyed them regarding clinical characteristics, vitiligo treatment, quality of life (QoL), and mental health. A total of 1151 patients were surveyed in EU5 countries (France, n = 250; Germany, n = 250; Italy, n = 200; Spain, n = 200; UK, n = 251). Half of patients (50. 3%) reported a family history of vitiligo, with highest rates in France (66. 4%) and Germany (58. 8%). Many patients experienced flares during periods of stress (65. 1%) or itching before/during a flare (61. 5%), with highest rates in Germany (78. 4%/78. 8%, respectively; P
Open Access PDF
| Concepts | Keywords |
|---|---|
| Dermatol | Disease burden |
| Eu5 | Patient history |
| Germany | Quality of life |
| Italy | Survey |
| Valiant | Treatment |
| Vitiligo |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Vitiligo |
| disease | MESH | autoimmune disease |
| drug | DRUGBANK | Bismuth subgallate |